PCI Biotech: Invitation to second quarter and first half 2020 results presentation
19 août 2020 03h21 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 19 August 2020 - PCI Biotech’s (OSE: PCIB) second quarter and first half 2020 interim report will be released on 26 August 2020 at 07.00 CEST. The interim report and presentation will be...
PCI Biotech: Publication of case report series from the Phase I study in bile duct cancer
19 août 2020 02h22 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 19 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that a case report series from the Phase I study with PCI Biotech's proprietary...
PCI Biotech: Update on the preclinical research collaboration agreement with AstraZeneca
13 juil. 2020 13h31 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 13 July 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced a 6 month extension of the evaluation period under its preclinical research...
PCI Biotech: Minutes from Annual General Meeting 2020
27 mai 2020 06h04 HE
|
PCI Biotech Holding ASA
Oslo, 27 May 2020. The Annual General Meeting in PCI Biotech Holding ASA took place today, 27 May 2020. All proposals were resolved by the Annual General Meeting as presented in the notice convening...
PCI Biotech: Disclosure of voting rights for Chairman of the Board
26 mai 2020 07h20 HE
|
PCI Biotech Holding ASA
Oslo, 26 May 2020. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall...
PCI Biotech: Notice of Annual General Meeting 2020
06 mai 2020 05h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway 6 May 2020 - The Annual General Meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park, on 27 May 2020 at 10:00am (CEST). Due to...
PCI Biotech: First quarter 2020 results
06 mai 2020 01h00 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 6 May 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first quarter 2020 results. Please find enclosed the report and...
PCI Biotech appoints Mr Ludovic Robin as Chief Business Officer
30 avr. 2020 03h54 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 30 April 2020 - PCI Biotech announces the appointment of Mr Ludovic Robin, PharmD, MBA, as Chief Business Officer (CBO). Mr Robin will also serve as a member of PCI Biotech’s executive...
PCI Biotech: Invitation to Q1 2020 results presentation
28 avr. 2020 07h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, 28 April 2020 - PCI Biotech’s Q1 2020 interim report will be released on 6 May, 2020 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on...
PCI Biotech Holding ASA publishes the Annual Report 2019
22 avr. 2020 02h00 HE
|
PCI Biotech Holding ASA
Oslo, Norway, April 22, 2020. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2019 and the report is attached. The Annual Report 2019 is also available on the...